

1 **TITLE:** Anatomical, Functional, and Hemodynamic Determinants of Increased Pulmonary
2 Capillary Wedge Pressure V-Wave Amplitude

3 **AUTHORS:** Mikhail Torosoff, Ciril Khorolsky, Riju Banerjee, Neil Yager

4 **Institution:** Albany Medical Center

5 **Address for correspondence:**

6 Mikhail Torosoff, MD, FACC

7 MC-44 Department of Medicine

8 Albany Medical Center

9 47 New Scotland AV

10 Albany, NY, 12203

11

12 **Phone number:** 518-262-5076

13 **Fax number:** 518-262-5082

14

15 **Email address:** torosom@amc.edu

16

17 **Abstract:**

18 Introduction: Increased pulmonary capillary wedge pressure (PCWP) V-wave amplitude has
19 been traditionally associated with significant mitral regurgitation (MR). However, increased
20 PCWP V-waves may also occur in patients with elevated left ventricular end-diastolic pressure
21 (LVEDP) or with dilated left atrium (LA). Interactions between MR, increased LVEDP, and LA
22 dilatation in the genesis of increased PCWP V-waves were not well investigated.

23 Material and Methods: It was a single-center cohort study of 153 consecutive hemodynamically
24 stable patients referred for invasive hemodynamic evaluation of dyspnea. Patients with
25 significant valvular disease other than MR, acute coronary syndromes (ACS), hemodynamic
26 instability, pericardial disease, and mechanical ventilation or mechanical LV support were
27 excluded.

28 Results: Study cohort included 41% males, 68.4+/-11.9 years old, 60% were on beta-adrenergic
29 antagonists and 69.3% were on afterload reduction therapy. PCWP V-wave amplitude was
30 significantly increased in patients with moderate or more severe MR ($p<0.001$), dilated LA
31 ($p=0.002$), with a trend towards increased V-wave amplitude in elevated >12 mmHg LVEDP
32 ($p=0.117$). There were no significant differences in age, gender, prevalence of LV dysfunction,
33 other co-morbidities, and/or E/e' ratio according to the MR degree, LA volume, and LVEDP. In
34 patients categorized according to moderate or more severe MR, dilated LA, and increased >12
35 mmHg LVEDP - the presence of any two of these abnormal parameters was associated with 50-
36 65% prevalence of elevated V-waves and reached 100% when all three were parameters were
37 abnormal ($p<0.002$).

38 Conclusions: In euvoletic patients undergoing elective invasive hemodynamic evaluation of
39 dyspnea, elevated PCWP V-waves are determined by three major pathophysiological
40 parameters: moderate or more severe MV regurgitation, LA dilatation, and elevated LVEDP.

41

42 **Keywords:** V-waves, CHF, left atrial volume, mitral regurgitation, LVEDP

43 **Introduction:**

44 With an aging population and improved treatment of acute and chronic cardiovascular diseases,
45 the prevalence of congestive heart failure (CHF) and mitral regurgitation (MR) is increasing
46 worldwide.¹ MR and CHF are commonly causative of and significantly contribute to each other's
47 pathophysiology and manifestation.^{2,3} Shared disease process and similarities in presentation
48 demand nuanced evaluation of MR in the setting of CHF to provide optimal medical,
49 interventional, and surgical management.

50 When suspected on clinical grounds, modern day MR quantification relies on echocardiographic
51 evaluation aided by invasive hemodynamic assessment when clinical and non-invasive findings
52 conflict.^{3,4} Increased pulmonary capillary wedge pressure (PCWP) V-wave amplitude has been
53 historically associated with severe MR,³ but while normal V-waves effectively rule out severe
54 MR, increased V-waves do not necessarily rule it in.^{5,6} It has been suggested that elevated left
55 ventricular end-diastolic pressure (LVEDP), a hallmark of CHF,⁷ may also contribute to increased
56 V-wave amplitude.^{8,9} In addition, while significant chronic MR leads to left atrial (LA)
57 dilatation,¹⁰ enlarged LA volume has been associated with increased V-waves in patients with¹¹
58 and without significant MR.¹²

59 Despite of these controversies, there is paucity of modern studies exploring interaction
60 between MR, elevated LVEDP, and increased LA volume in the genesis of increased PCWP V-
61 waves. To fill this knowledge gap, this study was conducted to evaluate and compare the effects
62 of MR, LVEDP, and LA volume on the PCWP V-wave amplitude in clinically stable, euvoletic CHF
63 patients on guideline-directed therapy (GDT) undergoing elective left and right cardiac
64 catheterization for dyspnea evaluation.

65 **Materials and Methods:**

66 This was a single tertiary care center study. The study cohort included consecutive patients
67 referred for left and right cardiac catheterization for evaluation of shortness of breath by the
68 treating physicians during the calendar years 2018-2022. Patients with acute coronary
69 syndromes (ACS), decompensated heart failure, non-MV valvular disease of moderate or worse
70 severity, MV stenosis of mild or worse severity, mechanical valve, pericardial effusion,
71 constriction, on mechanical ventilation, on mechanical support with intra-aortic balloon pump,
72 Impella®, or left ventricular assist device were excluded from the study.

73 The study was approved by the Institutional Review Board (IRB). The data was collected
74 prospectively for the first 76 patients. Interim IRB review waived the informed consent
75 requirement, as the collected data included only what was required for routine clinical care and
76 no experimental measurements or treatments were performed. Data on the remaining patients
77 was collected retrospectively. Clinical, echocardiographic, and invasive hemodynamic data was
78 obtained through chart review, hemodynamic tracing analysis, and echocardiographic image
79 processing.

80 **Hemodynamic data acquisition**

81 Cardiac catheterization was performed according to the standard of care utilizing sterile
82 technique, with standard catheters to assess pulmonary and right and left cardiac chamber

83 hemodynamics. Procedures were performed with a patient in a supine position. Transducers
84 were leveled and zeroed prior to procedure with mid-chest used as a reference point.
85 Hemodynamic data was collected according to the standard protocols, waveforms and values
86 were verified to ensure adequate data acquisition. Upward deflection of the PCWP tracing
87 following QRS was interpreted as a V-wave with maximum value measured during late
88 ventricular systole. PCWP and V-waves were assessed at end expiration. LVEDP, PCWP, and V-
89 wave values were recorded in millimeters of mercury (mmHg).

90 **Echocardiographic data acquisition**

91 Complete transthoracic echocardiograms were acquired in the ICAEL-accredited non-invasive
92 imaging laboratory by certified sonographers and permanently stored off-line for the
93 subsequent interpretation. The median time interval between invasive hemodynamic
94 assessment and echocardiographic evaluation was 4+/-5.7 days, in 124/153 (81%) patients
95 within 4 weeks interval. Echocardiograms were interpreted by the National Board of
96 Echocardiography (NBE) certified cardiologists independently from the study, at the time when
97 the test was performed for clinical indications. MR, LV ejection fraction and filling pressure, and
98 left atrial volume evaluation was performed in accordance with American Society of
99 Echocardiography Recommendations.^{4,13,14} Specifically, left atrial volume was determined by 2D-
100 biplane method based on maximal end-systolic left atrial areas obtained in the carefully
101 selected apical four chamber and apical two chamber views.¹³ LA was defined as dilated if LA
102 volume exceeded 50 ml.¹³ Transmitral peak E-flow velocity was measured in the apical 4
103 chamber view using pulsed wave Doppler and e' tissue Doppler velocity was obtained from the
104 apical 4 chamber view by placing pulsed Doppler sampling volume in the basal septal and left
105 ventricular lateral myocardial segments.¹⁴

106 **Results:**

107 Demographics and clinical characteristics are noted in Table 1. Moderate or worse MR was
108 present in 20% (Table 1) but more than 50% of the patients manifested with V-waves greater
109 than 20 mmHg and in 27% of patients the V-wave exceeded PCWP by 7 mmHg or more (Table
110 1). V-wave amplitude was significantly increased in patients with moderate or more significant
111 MR (Figure 1, Panel A, $p<0.001$) or with dilated LA (Figure 1, Panel B, $p=0.002$). There was a
112 trend towards increased V-wave amplitude in patients with elevated LVEDP (Figure 1, Panel C,
113 $p=0.117$).

114 Crosstabulation of the cohort according to the LA volume and degree of MR revealed three
115 distinct patient populations, (1) patients with normal LA volume with less than moderate MR
116 ($n=36/153$, 26%), (2) patients with dilated LA and less than moderate MR ($85/153$, 54%), and (3)
117 patients with moderate to severe MR ($31/153$, 20%) with all but one with dilated LA. Within
118 these three patient groups, when compared to patients with less than moderate MR and with
119 normal LA volume, LVEDP was significantly elevated (Figure 2, panel A, $p=0.039$) and V-waves
120 exceeding PCWP by 7 mmHg were significantly more common in patients with moderate or
121 more severe MR and dilated LA (Figure 2, panel B, $p=0.002$).

122 To analyze effects of LA volume, degree of MR and LVEDP on V-waves, the cohort was then
123 subdivided into 6 anatomical, functional, and hemodynamic profiles according to the LA
124 volume, degree of MR, and LVEDP (Table 2). Demographic and clinical characteristics were very
125 similar between these six profiles, except for higher E/e' ratio and lower hemoglobin level in
126 patients with dilated LA, significant MR, or elevated LVEDP (Table 2, $p < 0.001$ and $p = 0.008$,
127 respectively). Consistent with a compensated volume status required for study enrollment,
128 average E/e' ratio was significantly less than 14 in all patient profiles (Table 2).

129 Effects of LA volume, degree of MR, and LVEDP on prevalence of elevated V-waves were highly
130 significant (Figure 3, $p < 0.002$). When the MR degree was moderate or worse, LA was dilated,
131 and LVEDP was elevated, increased > 20 mmHg V waves were present in all patients (Figure 3,
132 profile 6). V waves > 20 mmHg were also noted in two-thirds of patients with dilated LA and
133 elevated LVEDP or if MR of moderate or worse in severity, but with a normal LVEDP (Figure 3,
134 profiles 4 and 5). Finally, V waves > 20 mmHg were present in half of the patients with less than
135 moderate MR and dilated LA or elevated LVEDP (Figure 3, profiles 2 and 3).

136 Table 1. Demographic, clinical, and hemodynamic characteristics.

Characteristic	Value
Age, mean – years old	68.4 +/- 11.9
Male sex — no. (%)	64/153 (41.8)
Body Mass Index, mean – kg/m ²	29.4 +/- 7.0
Coexisting condition — no. (%)	
Coronary artery disease	97/153 (63.4)
Coronary artery bypass graft surgery	29/153 (18.9)
Hypertension	113/153 (73.9)
Diabetes	54/153 (35.3)
Atrial fibrillation	42/153 (27.5)
Ventricular pacemaker	9/153 (5.9)
Hemoglobin, mean – g/dL	12.6 +/- 2.2
Brain natriuretic peptide, mean – pg/ml	942 +/- 1103
Glomerular filtration rate, mean – ml/min	72.9 +/- 42.0
Medical Therapy — no./total no. (%)	
Beta-adrenergic antagonists	92 (60.1)
ACE-I or ARB, or ARNI, or Hydralazine and Nitrates	106 (69.3)
Aldosterone antagonists	16 (10.4)
Loop diuretics	68 (44.4)
Thiazides	14 (9.2)
Systolic blood pressure, mean – mmHg	123.4 +/- 25.8
Diastolic blood pressure, mean – mmHg	65.9 +/- 17.2
Heart rate, mean – beats per minute	80.2 +/- 16.4
Left ventricular ejection fraction, mean – %	46.2 +/- 15.9
Left ventricular ejection fraction < 35 % — no. (%)	45/153 (29.4)
Left atrial volume, mean – ml	72.3 +/- 29.3
Left atrial volume >50ml, no. (%)	116/153 (75.8)
Left atrial volume indexed by BSA, mean – ml/m ²	36.1 +/- 14.6
Left atrial volume indexed by BSA >34ml/m ² , no. (%)	72/153 (47.1)
Mitral regurgitation, moderate or more severe, no. (%)	31/152 (20.4)
E/e', mean	3.880 +/- 2.015
Cardiac output, mean – L/min	6.0 +/- 1.7
Cardiac index, mean – L/min/m ²	3.0 +/- 0.7
Left ventricular end-diastolic pressure (LVEDP), mean – mmHg	13.5 +/- 8.7
Left ventricular end-diastolic pressure >12 mmHg, no. (%)	58/126 (46.0)
Mean pulmonary artery pressure, mean – mmHg	19.8 +/- 8.3
Pulmonary capillary wedge pressure (PCWP), mean – mmHg	15.9 +/- 8.6
V-wave, mean – mmHg	22.1 +/- 11.7
V-wave >20 mmHg, no. (%)	81/150 (54)
V-wave and mean PCWP difference >7mmHg, no. (%)	40/150 (26.7)

137 *) Plus-minus values are means ± standard deviations

138 Table 2. Demographic, clinical, and hemodynamic characteristics according to the structural and functional categories

Parameter	Less than moderate MR				Moderate or severe MR		p-value
	LA Volume <50 ml		LA Volume ≥50 ml				
	LVEDP 0-12 mmHg	LVEDP >12 mmHg	LVEDP 0-12 mmHg	LVEDP >12 mmHg	LVEDP 0-12 mmHg	LVEDP >12 mmHg	
	Profile 1	Profile 2	Profile 3	Profile 4	Profile 5	Profile 6	
Age, mean – ml	66.8+/-9.8	66.7+/-12.5	68.4+/-10.3	67.4+/-12.9	70.4+/-11.9	59.1+/-14.3	0.175
Male sex — no. (%)	7/17 (41.2)	6/18 (33.3)	17/38 (44.7)	13/27 (48.1)	5/12 (41.7)	1/13 (7.7)	0.211
Body Mass Index, mean – kg/m ²	27.9+/-5.6	6.9+/-1.6	7.5+/-1.2	8.4+/-1.6	4.7+/-1.4	5.4+/-1.5	0.389
Coexisting condition — no. (%)							
Coronary artery disease	11/17 (64.7)	13/18 (72.2)	22/38 (57.9)	17/27 (62.9)	6/12 (50.0)	9/13 (69.2)	0.827
Coronary artery bypass graft surgery	3/17 (17.6)	4/18 (22.2)	7/38 (18.4)	3/27 (11.1)	3/12 (25)	4/13 (30.8)	0.751
Hypertension	12/17 (70.6)	11/18 (61.1)	26/38 (66.4)	21/27 (77.8)	10/12 (83.3)	12/13 (92.3)	0.389
Diabetes	6/17 (35.3)	6/18 (33.3)	16/38 (42.1)	12/27 (44.4)	2/12 (16.7)	5/13 (38.5)	0.655
Atrial fibrillation	3/17 (17.6)	4/18 (22.2)	10/38 (26.3)	10/27 (37.0)	6/12 (50)	2/13 (15.4)	0.282
Ventricular pacemaker	1/17 (5.9)	2/18 (11.1)	5/38 (13.2)	0/27 (0)	1/12 (8.3)	0/13 (0)	0.347
LV ejection fraction, mean – %	52.1+/-12.7	48.6+/-13.9	45.9+/-16.6	47.8+/-16.3	42.7+/-17.1	36.9+/-16.2	0.155
LV ejection fraction <35 % — no. (%)	2/17 (11.8)	4/18 (22.2)	12/38 (31.6)	6/27 (22.2)	5/12 (41.7)	8/13 (61.5)	0.05
Hemoglobin, mean – g/dL	13.6+/-1.4	13.2+/-1.9	12.5+/-2.4	12.1+/-2.1	13.7+/-1.9	11.3+/-2.2	0.008
Brain natriuretic peptide, mean – pg/ml	423+/-556	698+/-1299	953+/-981	733+/-1241	880+/-616	1469+/-616	0.334
Glomerular filtration rate, mean – ml/min	66.5+/-25.7	69.7+/-37.3	76+/-43.9	63.7+/-53	70.4+/-16.3	55.5+/-48.7	0.105
E/e'	2.5+/-1.0	3.0+/-1.0	3.7+/-1.7	3.9+/-1.8	5.1+/-2.8	5.7+/-2.5	<0.001

139 *) Plus-minus values are means ± standard deviations

140 **Discussion:**

141 The prevalence of MR and CHF is increasing worldwide.¹ Both MR and CHF manifest with
142 shortness of breath and pulmonary congestion caused by synergistic disease processes leading
143 to decreased LV and LA compliance with increased LV, LA, and pulmonary capillary wedge
144 pressures.^{2,3} Optimal medical, interventional, and surgical outcomes in patients with co-existing
145 MR and CHF demand a thorough understanding of cardiac hemodynamics in this complex
146 disease process. While modern diagnosis and quantification of MR relies on non-invasive
147 echocardiographic evaluation, left and right cardiac catheterization is employed when
148 noninvasive testing results are inconclusive or conflict with clinical findings.^{2,3}

149 PCWP V-waves reflect a rise in the LA pressure in late systole. Increased V-waves on PCWP
150 tracing have been classically attributed to significant MR,³ however, clinical practice and prior
151 research suggest that increased V waves may also occur without significant MR.^{5,6,8,9} Our study
152 of stable euvoletic patients revealed three major contributors to increased PCWP V-wave
153 amplitude, i.e. rise in the LA pressure in late systole: anatomical - LA dilatation, functional - MR
154 of moderate or worse severity, and hemodynamic - elevated LVEDP synonymous with elevated
155 diastolic LA pressure. Increased V-waves were unlikely when all these parameters are normal.
156 Alternatively, we have observed increased V-waves in all patients when all three of these
157 parameters were abnormal. Any combination of moderate or more severe MR, dilated LA, and
158 elevated LVEDP was associated with 50-65% prevalence of increased V-waves.

159 Increased LV end-diastolic, LA, and pulmonary capillary wedge pressures with dilated LA are
160 hallmarks of chronic CHF.⁷ Similarly, chronic hemodynamically significant MR imposes volume
161 load on the LV and LA, with eventual LV and LA enlargement and rise in LVEDP, LA, and PCWP.³
162 Due to the similarities in the disease process, elevated LVEDP is not specific in diagnosis of CHF
163 or MR, but rather reflects decreased LV and LA compliance.^{2,3} From the standpoint of central
164 hemodynamic assessment, increased LVEDP and LA pressure are inferred when PCWP is
165 elevated in the absence of significant mitral valve stenosis. Underscoring the importance of
166 elevated LVEDP in genesis of increased V-waves, in our study of patients with less than
167 moderate MR, increased V-waves were noted in 50% of patients with elevated LVEDP and
168 normal LA volume and in 65% when elevated LVEDP was combined with dilated LA. It is
169 important to note that our study included patients that were euvoletic and hemodynamically
170 stable and treated with afterload reduction, beta-adrenergic antagonists, and diuretics. It is
171 likely that volume overloaded CHF patients with elevated LVEDP would have an even higher
172 prevalence of increased V-waves. From the clinical perspective, as normal LVEDP has been
173 associated with reduced prevalence of increased V-waves even in patients with significant MR
174 and/or dilated LA, improved hemodynamics and decreased V-waves should be expected with
175 meticulous volume management and aggressive LVEDP lowering.

176 Dilated LA is universally seen in patients with advanced CHF and in chronic hemodynamically
177 significant MR. LA dilatation reflects chronic volume and pressure load on the LA, which may be
178 due to increased LVEDP in CHF, increased preload due to MR, or a combination of both.^{2,3}

179 Understanding importance of abnormal LA structure and function in central hemodynamics
180 changes attributable to CHF and MR continues to evolve.¹⁰⁻¹² Historically, chronic LA dilatation
181 was thought to decreased LA pressure rise due significant MR.⁵ However, recent studies
182 suggested that chronic atrial dilatation and decreased LA compliance augment transmission of
183 MR-related systolic pressure increase into pulmonary capillary bed causing increased V-wave
184 amplitude.^{10,12} In our study, LA dilatation was associated with increased V-wave amplitude,
185 especially in patients with co-existing MR of moderate or worse severity. Comparing effects of
186 increased LVEDP and dilated LA on V-waves, prevalence of increased V-waves was
187 approximately 50% if either LVEDP was elevated or LA was dilated, and 65% if LVEDP was
188 elevated in the setting of dilated LA. This observation indicates that compliance in dilated LA is
189 decreased and dilated LA is unable to accommodate any additional volume without significant
190 rise in pressure, thus generating increased V-waves.

191 Interpreting V-waves may be difficult in patients with elevated PCWP, when the absolute V-wave
192 amplitude may be less important than the difference between V-waves and mean PCWP.^{5,9} In
193 patients with elevated PCWP subtracting mean PCWP from the V-wave amplitude promises to
194 reduce effects of elevated LVEDP on V-waves. The absolute difference between peak V-wave
195 and mean PCWP consistent with hemodynamically significant MR has not been established with
196 the values above 5-7 mmHg generally considered to be meaningful.^{5,9} When V-waves exceeding
197 LVEDP by 7 mmHg or more were considered, only 50% of our study patients with moderate or
198 more severe MR had significantly increased V-waves. These findings underscore the limited
199 sensitivity of V-waves in MR diagnosis and the important contribution of elevated LVEDP to the
200 pathophysiology of increased V-waves.

201 **Study Limitations and Strengths:**

202 Our study findings are limited to euvolemic patients referred for cardiac catheterization when
203 invasive assessment was requested for clinical indications. Prevalence of increased V-waves may
204 be different in patients who are hemodynamically unstable, require mechanical circulatory
205 support and have significant valvular disease other than mitral regurgitation. Furthermore,
206 additional hemodynamic and pathologic parameters that may affect V-wave amplitude. These
207 parameters and conditions may include atrial arrhythmias, ventricular conduction abnormalities
208 and atrio-ventricular blocks, acute LV dysfunction in the setting of myocardial ischemia and non-
209 ischemic conditions like myocarditis and stress cardiomyopathy.

210 We are unable to conclusively evaluate the effect of heart failure GDMT on V-waves. In our
211 study, two-thirds of patients were on afterload reduction and beta-adrenergic antagonists, but
212 the treatment was not randomized. In addition, many patients were on diuretics with a small
213 fraction on aldosterone-receptor antagonists, and only a few on SGLT-2 inhibitors, as the data
214 was collected before the wide-spread acceptance of this treatment modality. Likewise, we
215 cannot speculate on effects of inotropes and/or mechanical left ventricular support on V-waves,
216 which will require a separate study specifically aimed at investigating these extremely
217 vulnerable patients.

218 With limitations as noted above, our findings are biologically plausible and reveal highly
219 significant differences in the study endpoints despite a modest sample size. These findings
220 contribute to and extend the body of knowledge on complex hemodynamic changes
221 attributable to heart failure and mitral regurgitation.

222 **Conclusions:**

223 Our data indicates that in euvolemic patients undergoing elective invasive hemodynamic
224 evaluation, increased V-wave amplitude is determined by three major pathophysiological
225 parameters: 1) anatomy of LA, normal vs. dilated, 2) degree of MR, less than moderate vs.
226 moderate or more severe, and 3) hemodynamics of LV, normal or elevated LVEDP. In our study,
227 increased V-waves were very unlikely when all these parameters are normal. Any combination
228 of 2 of these abnormal parameters was associated with 50-65% prevalence of increased V-
229 waves and reached 100% when all three were abnormal. From the clinical perspective, these
230 findings suggest that comprehensive interpretation of PCWP hemodynamic data should include
231 anatomy of the left atrium, mitral valve function, and LV filling parameters.

232 **References:**

- 233 1. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ,
234 Boehme AK, Buxton AE, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From
235 the American Heart Association. *Circulation*. 2023;147:e93-e621. doi:
236 10.1161/CIR.0000000000001123
- 237 2. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH,
238 Dunlay SM, Evers LR, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure:
239 A Report of the American College of Cardiology/American Heart Association Joint Committee on
240 Clinical Practice Guidelines. *Circulation*. 2022;145:e895-e1032. doi:
241 10.1161/CIR.0000000000001063
- 242 3. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, 3rd, Gentile F, Jneid H, Krieger EV,
243 Mack M, McLeod C, et al. 2020 ACC/AHA Guideline for the Management of Patients With
244 Valvular Heart Disease: Executive Summary: A Report of the American College of
245 Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
246 *Circulation*. 2021;143:e35-e71. doi: 10.1161/CIR.0000000000000932
- 247 4. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, Hahn RT, Han Y,
248 Hung J, Lang RM, et al. Recommendations for Noninvasive Evaluation of Native Valvular
249 Regurgitation: A Report from the American Society of Echocardiography Developed in
250 Collaboration with the Society for Cardiovascular Magnetic Resonance. *J Am Soc Echocardiogr*.
251 2017;30:303-371. doi: 10.1016/j.echo.2017.01.007
- 252 5. Fuchs RM, Heuser RR, Yin FC, Brinker JA. Limitations of pulmonary wedge V waves in diagnosing
253 mitral regurgitation. *Am J Cardiol*. 1982;49:849-854. doi: 10.1016/0002-9149(82)91968-3
- 254 6. Snyder RW, 2nd, Glamann DB, Lange RA, Willard JE, Landau C, Negus BH, Hillis LD. Predictive
255 value of prominent pulmonary arterial wedge V waves in assessing the presence and severity of
256 mitral regurgitation. *Am J Cardiol*. 1994;73:568-570. doi: 10.1016/0002-9149(94)90335-2
- 257 7. Iskandrian AS, Segal BL, Hakki AH. Left ventricular end-diastolic pressure in evaluating left
258 ventricular function. *Clin Cardiol*. 1981;4:28-33. doi: 10.1002/clc.4960040107
- 259 8. Pichard AD, Diaz R, Marchant E, Casanegra P. Large V waves in the pulmonary capillary wedge
260 pressure tracing without mitral regurgitation: the influence of the pressure/volume relationship
261 on the V wave size. *Clin Cardiol*. 1983;6:534-541. doi: 10.1002/clc.4960061104
- 262 9. Kageji Y, Oki T, Iuchi A, Tabata T, Ito S. Relationship between pulmonary capillary wedge V wave
263 and transmitral and pulmonary venous flow velocity patterns in various heart diseases. *J Card*
264 *Fail*. 1996;2:215-222. doi: 10.1016/s1071-9164(96)80044-3
- 265 10. Pape LA, Price JM, Alpert JS, Ockene IS, Weiner BH. Relation of left atrial size to pulmonary
266 capillary wedge pressure in severe mitral regurgitation. *Cardiology*. 1991;78:297-303. doi:
267 10.1159/000174808
- 268 11. Pizzarello RA, Turnier J, Padmanabhan VT, Goldman MA, Tortolani AJ. Left atrial size, pressure,
269 and V wave height in patients with isolated, severe, pure mitral regurgitation. *Cathet Cardiovasc*
270 *Diagn*. 1984;10:445-454. doi: 10.1002/ccd.1810100505
- 271 12. Purga SL, Karas MG, Horn EM, Torosoff MT. Contribution of the left atrial remodeling to the
272 elevated pulmonary capillary wedge pressure in patients with WHO Group II pulmonary
273 hypertension. *J Echocardiogr*. 2019;17:187-196. doi: 10.1007/s12574-018-0410-8
- 274 13. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E,
275 Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber quantification by
276 echocardiography in adults: an update from the American Society of Echocardiography and the
277 European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28:1-39 e14. doi:
278 10.1016/j.echo.2014.10.003

279 14. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, 3rd, Dokainish H, Edvardsen T, Flachskampf FA,
280 Gillebert TC, Klein AL, Lancellotti P, et al. Recommendations for the Evaluation of Left Ventricular
281 Diastolic Function by Echocardiography: An Update from the American Society of
282 Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc*
283 *Echocardiogr.* 2016;29:277-314. doi: 10.1016/j.echo.2016.01.011

284

Figure 1. Effects of mitral regurgitation, left atrial volume, and LVEDP on PCWP V-wave amplitude.




Figure 1 Caption: V-wave amplitude was significantly increased in patients with moderate or more significant MR (Panel A, $p < 0.001$) or dilated LA (Panel B, $p = 0.002$). There was a trend towards increased V-wave amplitude in patients with elevated LVEDP (Panel C, $p = 0.117$).

Figure 2. Effects of mitral regurgitation and left atrial size on LVEDP and prevalence of V-waves exceeding PCWP by 7 mmHg.




Figure 2 Caption: Moderate or more severe MR and dilated LA were associated with elevated LVEDP (Panel A, $p=0.039$) and increased prevalence of V-wave exceeding PCWP by 7 mmHg (Panel B, $p=0.002$).

Figure 3. Effects of left atrial size, mitral regurgitation, and elevated LVEDP on PCWP V-wave amplitude




Figure 3 Caption: LA volume, MR, and elevated LVEDP significantly affected prevalence of elevated V-waves (Panel A, $p < 0.002$). In moderate or more severe MR with dilated LA and elevated LVEDP, V waves > 20 mmHg were present in all patients (Panel A, profile 6). Elevated > 20 mmHg V waves were also noted in two-thirds of patients with dilated LA and elevated LVEDP or if MR was moderate or more severe, but LVEDP was normal (Panel A, profiles 4 and 5), and in half of the patients with less than moderate MR but dilated LA or with elevated LVEDP (Panel A, profiles 2 and 3).